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Palbociclib: a first-in-class CDK4/CDK6 inhibitor




Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal
women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy.
In addition, the combination of palbociclib with fulvestrant resulted in superior outcome than fulvestrant alone in
those who had progressed during prior endocrine therapy. This research highlight summarized the current
development of CDK4/CDK6 inhibitors and future directions in the treatment of advanced hormone-receptor-positive
breast cancer.
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Personalizing the use of cancer therapeutics is a major
focus of current cancer research [1–6]. The pioneering
work of Finn and Slamon showed activity of palbociclib
as an inhibitor of cyclin-dependent kinase (CDK) 4 and
6 which reduced cellular proliferation of estrogen recep-
tor (ER)-positive breast cancer cell lines by blocking
progression of cells from G1 into S phase of the cell
cycle [7]. Palbociclib was approved by the FDA for use
in combination with letrozole for the treatment of post-
menopausal women with ER-positive, human epidermal
growth factor receptor 2 (HER2)-negative advanced
breast cancer as initial endocrine-based therapy for their
metastatic disease.
The approval of palbociclib is based on a phase 2
PALOMA-1/TRIO-18 study, which is a randomized,
multicenter, open-label trial in postmenopausal women
with HR-positive, HER2-negative, advanced breast cancer
who had not received previous systemic treatment for
advanced disease. The trial enrolled 165 patients ran-
domly allocated to receive either palbociclib plus letro-
zole or letrozole alone [8]. Among the 165 patients,
43 % had received chemotherapy and 33 % had received
anti-hormonal therapy as a neoadjuvant or adjuvant
treatment. Forty-nine percent of patients had no prior
systemic therapy in the neoadjuvant or adjuvant setting.
The majority of patients (98 %) had metastatic disease,
48 % had visceral disease, 75 % had bone disease, and
19 % had bone-only disease. Median progression-free
survival was 10.2 months (95 % CI 5.7–12.6) for the
letrozole group and 20.2 months (13.8–27.5) for the
palbociclib plus letrozole group (HR 0.488, 95 % CI
0.319–0.748; one-sided p = 0.0004), which correlates to
a doubled PFS in favor of the combination group. The
overall survival is unknown and the follow-up is
ongoing.
In addition to the benefit of palbociclib as initial endo-
crine-based therapy for metastatic hormone-receptor-
positive breast cancer, PALOMA3 trial evaluated 521
patients with advanced hormone-receptor-positive,
HER2-negative advanced breast cancer that had re-
lapsed or progressed during prior endocrine therapy.
Patients were randomly assigned in a 2:1 ratio to re-
ceive palbociclib and fulvestrant or placebo and fulves-
trant [9]. PALOMA3 study concluded that palbociclib
with fulvestrant resulted in longer progression-free sur-
vival and a relatively higher quality of life than fulves-
trant alone in patients with advanced hormone-receptor-
positive breast cancer that had progressed during prior
endocrine therapy. The median progression-free survival
was 9.2 months with palbociclib-fulvestrant and 3.8 months
with placebo-fulvestrant (p < 0.0001, 95 % CI).
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Consistent benefit from palbociclib was seen in all
subgroups analyzed, with similar benefit in progression-
free survival adding palbociclib in both premenopausal
and postmenopausal women. Translational research for
markers that might predict which group of patients ben-
efits most is ongoing.
In addition to the favorable outcome from the clinical
trials using palbociclib, other small molecule inhibitors
of CDK4/6 are being studied in hope for developing
more potent agents. In preclinical models, LEE011
(ribociclib) has demonstrated a dose-dependent antitu-
mor activity that tracks well with CDK4/6 inhibition
[10, 11]. Ribociclib is currently being evaluated in HR-
positive breast cancer with letrozole and PI3K inhibitor
BYL719 [12, 13]. A phase III study evaluating the com-
bination of ribociclib with letrozole in HR-positive,
HER2-negative breast cancer is ongoing (MONA-
LESSA-2, NCT01958021). Other phase III studies in-
vestigating ribociclib in combination regimens for the
treatment of women with HR-positive, HER2-negative
advanced breast cancer are ongoing (MONALEESA-3,
NCT02422615; [14]).
Abemaciclib (LY2835219) is another selective oral
CDK4/6 inhibitor that is being developed in preclinical
settings and clinical trials [15–17]. The combination of
abemaciclib plus fulvestrant was evaluated in a small
study (n = 13), which showed that combination therapy
was well tolerated [18]. Several studies are planned
which include a phase III randomized double-blind pla-
cebo-controlled trial of nonsteroidal aromatase inhibitor
with or without abemaciclib in previously untreated ad-
vanced hormone-sensitive breast cancer (MONARCH 3,
NCT02246621) [19]. A randomized double-blind placebo-
controlled phase III study will compare the combination
of abemaciclib with fulvestrant versus fulvestrant alone
(MONARCH 2, NCT02107703) to investigate the benefit
of abemaciclib in combination with endocrine therapy
with a primary endpoint of PFS.
Future directions also include using the CDK4 and
CDK6 inhibitors in the adjuvant and neoadjuvant therapy
settings. A neoadjuvant trial investigating the combination
of abemaciclib and aromatase inhibitor in locally
advanced ER-positive, HER2-negative breast cancer
(neoMONARCH, NCT02441946) is ongoing.
The results of the PALOMA 1/TRIO 18 study led to
accelerated FDA approval of palbociclib in combination
with letrozole in first line advanced ER+/HER2-breast
cancer. The doubled PFS benefit observed in this ran-
domized trial was impressive, but it still is awaiting
confirmation from the phase III PALOMA-2 study. The
PALOMA 3 study clearly showed that adding palbociclib
to fulvestrant resulted in substantially longer progression-
free survival than fulvestrant alone in patients with ad-
vanced HR-positive and HER2-negative breast cancer that
had progressed during prior endocrine therapy, regardless
of menopause status. In addition, the combination therapy
is associated with relatively higher quality of life than with
fulvestrant alone. Neutropenia was the most common
adverse event in patients receiving palbociclib with low
incidence of febrile neutropenia in both treatment
groups. Although the combination of aromatase inhibitor
with fulvestrant or everolimus remain excellent treatments
for this group of patients [1, 20], PALOMA 3 offers an
excellent alternative therapy for both premenopausal and
postmenopausal patients who had progressed with prior
endocrine therapy. Palbociclib and other CDK4/6 inhibi-
tors being developed offer a new era of treatment for
hormone-receptor-positive advanced breast cancer.
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